Adimab vs Paratus Sciences
Adimab vs Paratus Sciences, compared side by side on 18 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Adimab is on 53/100 and Paratus Sciences on 46/100.
Where each one leads
Adimab
- our overall score: 53/100 against 46/100
- domain rating: 39/100 against 27/100
- headcount: 139 against 19
- LinkedIn following: 8,423 against 3,538
Paratus Sciences
Leads on none of the measures we hold for both companies.
At a glance
| Measure | Adimab | Paratus Sciences |
|---|---|---|
| What it is | Adimab is a biotechnology company that discovers and develops therapeutic antibodies using its proprietary yeast-based platform. | Biotech startup leveraging bat biology for novel therapeutics in immunology and cardiometabolic diseases. |
| Category | Biotech, Drug Discovery, Antibody Discovery, Therapeutic Antibodies | Biotech, Drug Discovery, Genomics, Informatics |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Platform |
| Founded | 2007 | 2021 |
| Headquarters | Lebanon, United States | New York, United States |
| Status | Active | Active |
Size, funding and growth
| Measure | Adimab | Paratus Sciences |
|---|---|---|
| Employees | 139 | 19 |
| Total funding | $105M | Not published |
| Latest round | Series B | Not published |
| LinkedIn followers | 8,423 | 3,538 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Adimab | Paratus Sciences |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 53/100 | 46/100 |
| Traction | 60/100 | 13/100 |
| Team | Not published | 70/100 |
| Community | Not published | 15/100 |
| Search visibility | 20/100 | 20/100 |
| Quality | 68/100 | 58/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (40/100) | F (39/100) |
| Domain ratingLink authority, 0-100 | 39/100 | 27/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Adimab | Paratus Sciences |
|---|---|---|
| Hosting | AWS | Not detected |
| CDN | Not detected | Cloudflare |
| CMS | WordPress | WordPress |
| Frameworks | Jquery, Bootstrap | Jquery |
| Analytics | Google Tag Manager, Linkedin Insight | Google Analytics 4 |
| Support stack | HubSpot | Not detected |
Adimab vs Paratus Sciences: common questions
Which is better, Adimab or Paratus Sciences?
On our 0-100 score Adimab rates higher (53/100 against 46/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 18 data points above: read the rows that match what you are buying for.
How do Adimab and Paratus Sciences compare on the numbers?
Adimab leads on our overall score (53/100 against 46/100), domain rating (39/100 against 27/100), headcount (139 against 19), LinkedIn following (8,423 against 3,538).
Read the full Adimab review and pricing or the Paratus Sciences review and pricing. You can also browse other Adimab alternatives we track.